Exploiting the promiscuity of imatinib

Posted by rob on April 14, 2009 under Uncategorized | Comments are off for this article

The protein kinase inhibitor imatinib, also known as Gleevec, has been a notable success in treating chronic myelogenous leukemia. A recent paper in BMC Structural Biology reports a 1.75 Å crystal structure of imatinib bound to the oxidoreductase NQO2 and reveals insights into the binding specificity and the off-target effects of the inhibitor. (Source: Journal of Biology)